While AI's impact on business is significant, the ultimate catalyst for market euphoria will be its application in healthcare. When AI-driven drug discovery makes 'living forever' a tangible possibility, it will unlock an unprecedented level of investor optimism.
The most immediate AI milestone is not singularity, but "Economic AGI," where AI can perform most virtual knowledge work better than humans. This threshold, predicted to arrive within 12-18 months, will trigger massive societal and economic shifts long before a "Terminator"-style superintelligence becomes a reality.
Speculative manias, like the AI boom, function like collective hallucinations. The overwhelming belief in future demand becomes self-fulfilling, attracting capital that builds tangible infrastructure (e.g., data centers, fiber optic cables) long before cash flows appear, often leaving lasting value even after the bubble bursts.
Most companies use AI for optimization—making existing processes faster and cheaper. The greater opportunity is innovation: using AI to create entirely new forms of value. This "10x thinking" is critical for growth, especially as pure efficiency gains will ultimately lead to a reduced need for human workers.
The tech world is fixated on trivial AI uses while monumental breakthroughs in healthcare go underappreciated. Innovations like CRISPR and GLP-1s can solve systemic problems like chronic disease and rising healthcare costs, offering far greater societal ROI and impact on longevity than current AI chatbots.
Beyond tackling fatal diseases to increase lifespan, a new wave of biotech innovation focuses on "health span"—the period of life lived in high quality. This includes developing treatments for conditions often dismissed as aging, such as frailty, vision loss, and hearing decline, aiming to improve wellbeing in later decades.
The most profound innovations in history, like vaccines, PCs, and air travel, distributed value broadly to society rather than being captured by a few corporations. AI could follow this pattern, benefiting the public more than a handful of tech giants, especially with geopolitical pressures forcing commoditization.
The life sciences investor base is highly technical, demanding concrete data and a clear path to profitability. This rigor acts as a natural barrier to the kind of narrative-driven, AI-fueled hype seen in other sectors, delaying froth until fundamental catalysts are proven.
AI is developing spatial reasoning that approaches human levels. This will enable it to solve novel physics problems, leading to breakthroughs that create entirely new classes of technology, much like discoveries in the 1940s led to GPS and cell phones.
For venture capitalists investing in AI, the primary success indicator is massive Total Addressable Market (TAM) expansion. Traditional concerns like entry price become secondary when a company is fundamentally redefining its market size. Without this expansion, the investment is not worthwhile in the current AI landscape.
While healthcare companies widely use AI for cost savings and R&D efficiency, it has not yet translated into measurable revenue or earnings growth. For equity investors, there are easier, more direct ways to invest in the AI trend, making healthcare a poor proxy for the theme until its financial impact becomes clear.